REVIEW

Temozolomide in aggressive pituitary adenomas and carcinomas

Leon D. Ortiz,1 Luis V. Syro,1 Bernd W. Scheithauer (in memoriam),1II Fabio Rotondo,IV Humberto Uribe,IV Camilo E. Fadul,VI Eva Horvath,IV Kalman KovacsIV

1Instituto de Cancerologia, Clinica Las Americas, Division of Neuro-oncology, Medellin, Colombia. 11Hospital Pablo Tobon Uribe and Clinica Medellin, Department of Neurosurgery, Medellin, Colombia. IV Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA. 11University of Toronto, St Michael’s Hospital, Department of Laboratory Medicine, Toronto, Ontario, Canada. 11Clinica SOMA, Department of Neurosurgery, Medellin, Colombia. 1IV Dartmouth Hitchcock Medical Center, Department of Medicine (Section of Hematology/Oncology) and Neurology, Lebanon, New Hampshire, USA.

Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophyseal tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6-methylguanine-DNA methyltransferase immunoreexpression and therapeutic response. Alternatively, high-level O6-methylguanine-DNA methyltransferase immunoreexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms.

KEYWORDS: Pituitary adenoma; Pituitary carcinoma; MGMT; Temozolomide; Review.

Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics. 2012;67(S1):119-123.

E-mail: lvsyro@une.net.co
Tel.: 57 4 231 9099

INTRODUCTION

Patients with aggressive pituitary adenomas are difficult to clinically manage. Frequently, these adenomas are large, rapidly growing and invasive to their surroundings. These tumors also present problems due to incomplete resection and recurrence. Reoperation, pharmacological treatment and radiotherapy are routinely employed, often in combination. Nevertheless, many patients experience tumor regrowth (1). Endocrinologically active adenomas, particularly prolactin (PRL)- and growth hormone (GH)-producing tumors, may become resistant to medical therapy, thus requiring multiple resections. Radiation and conventional chemotherapy are often employed in an attempt to achieve local tumor control, but the results are often disappointing.

Pituitary carcinomas are rare and present particular diagnostic and therapeutic challenges. All of these carcinomas are of large size, invasive and associated with craniospinal and/or systemic metastases. Multiple treatment approaches, including surgery, external beam radiotherapy, radiosurgery, adjuvant pharmacological therapy and various chemotherapeutic approaches, are palliative at best, achieving only temporary effects (2,3). Progression of the disease after the diagnosis of pituitary carcinoma is variable but often inexorable. Approximately 75% of patients with systemic metastasis die within 1 year of documented spread (4).

Recent publications have reported the efficacy of temozolomide for treating aggressive pituitary adenomas and carcinomas (5–29). In this review, we discuss the indications, results and side effects of temozolomide therapy.

Temozolomide

Temozolomide is a second-generation alkylating chemotherapeutic agent related to a series of imidazotetrazines that were originally synthesized in 1987 (30). Orally administered, it readily crosses the blood-brain barrier. At physiological pH, it undergoes rapid conversion to methyltri azeno-imidazole-carboxamide (MTIC), the active agent. It exerts its cytotoxic effects through methylation of DNA at the O6 position of guanine (31), which then mispairs with...
for five of every 28 days (5/28). Depletion of MGMT expression is a predictive marker of a favorable cisplatinum response for 7 days every other week (7/14) or at a dose of 85–100 mg/m²/day. Temozolomide is administered at a dose of 150 mg/m²/day for 21 consecutive days (21/28) (40). The anti-angiogenic effect of temozolomide can be optimized by administering low doses of the drug on a frequent or continuous schedule without extended interruptions (i.e., “metronomic” chemotherapy). Temozolomide can also be administered on a continuous, daily metronomic schedule, thus achieving MGMT depletion and improving the clinical response. This dose is generally 50 mg/m²/day without interruption (28/28). Other temozolomide schedules recommend administration every other week (7/14) or a 21-consecutive-day regimen that is administered every 28 days (21/28). Both are considered dose-dense regimens based on the Norton-Simon model of cell proliferation, which states that a dose of chemotherapy will have a fixed cell-kill rate regardless of the size of the tumor (39). Thus, decreasing the time interval between doses (i.e., increasing the dose density) improves efficacy by minimizing the opportunity for cellular regrowth between cycles (41). In these dose-dense regimens, temozolomide is administered at a dose of 150 mg/m²/day for 7 days every other week (7/14) or at a dose of 85–100 mg/m²/day for 21 consecutive days (21/28) (40). In reported pituitary cases, temozolomide was administered as mono-therapy in all but three cases. The standard 5/28 regimen was used in almost all instances except in the series of Bush et al. (23), in which a dose-dense, 21/28 schedule was used, and one case progressed to carcinoma, which was then treated using the metronomic 28/28 schedule (29). Temozolomide absorption is only minimally affected by food. Furthermore, no serious side effects have been reported. Common, non-hematological adverse effects are present, including nausea, vomiting, fatigue, headache and constipation, most of which are mild to moderate in severity.

As previously stated, MGMT is a DNA repair protein that reverses the effects of temozolomide therapy (42) by removing alkylating adducts, thereby counteracting its effects (43) and conferring resistance to the agent (44). Low-level expression in a wide variety of human tumors is thought to result from epigenetic silencing by hypermethylation of the MGMT gene promoter (44,45). Low-level MGMT expression is a predictive marker of a favorable clinical outcome in patients with temozolomide-treated glioblastomas (46–48). Herein, we extend this observation to aggressive adenohypophysial tumors.

**Pituitary adenomas**

The first temozolomide-treated pituitary adenoma patient was reported in 2006 (7,8). The tumor, which was investigated using histological, immunohistochemical and electron microscopic techniques, showed significant post-therapeutic effects, including hemorrhage, necrosis, focal fibrosis, reduced mitotic activity, Ki-67 labeling and, surprisingly, neuronal transformation. MGMT immunoreexpression was completely absent. Subsequently, the case of a 41-year-old patient with an aggressive silent subtype 2 corticotroph adenoma was reported (10). It showed no morphological changes after temozolomide treatment. The tumor cell nuclei were immunopositive for MGMT. Based upon these results, it was suggested that MGMT immunoreexpression may predict the responsiveness of temozolomide therapy (10).

To the best of our knowledge, to date 30 cases of pituitary adenoma have been treated with temozolomide (7,16,18-20,22-26,28,29). Patient ages varied from 20 to 71 years (mean: 51 years). Aside from one tumor that was incidentally discovered in a patient with concomitant glioblastoma multiforme, all tumors were morphologically studied. The group included ten adrenocorticotrophic hormone (ACTH)-producing tumors, nine PRL-producing tumors, seven clinically non-functioning adenomas, two silent ACTH adenomas, and two GH-producing adenomas. The time between clinical presentation and onset of temozolomide treatment was between 2 and 23 years (mean: 10.7 years). Twenty-six of the 30 tumors had been irradiated previously. Aside from the incidentally discovered tumor in one patient, all other patients had undergone at least one operative procedure, the number ranging from 0 to 6 procedures (mean: 2.7). The response rate was 60% (18/30 patients). Debono et al. (11) reported the first case of a pituitary adenoma associated with multiple endocrine neoplasia type 1 (MEN1) that was treated with temozolomide. The 47-year-old man had primary hyperparathyroidism and a lesion at the head of the pancreas. Genetic analysis confirmed MEN1. The dopamine-resistant, prolactin-producing pituitary adenoma responded dramatically to temozolomide, demonstrating clinical, biochemical, and radiological improvements.

MGMT immunoreexpression was documented in 23 of the 30 patients. A high level of labeling was seen in six instances, an intermediate level in six instances, and a low level in 11 instances. Only one of six patients with high MGMT immunoreexpression responded to temozolomide. Two tumors with intermediate MGMT immunoreexpression did not respond, whereas none of the 11 tumors with low-level MGMT immunoreexpression responded favorably.

**Pituitary carcinomas**

Pituitary carcinomas are difficult to manage given their relentless growth and metastatic spread, despite the effects of multimodality therapy. The latter includes repeated surgeries, pharmacological manipulation, radiotherapy, and conventional chemotherapy (3,49), including various combinations of cis-platinum, etoposide and/or paclitaxel, but these have failed to achieve favorable clinical responses (2).

Initial reports of the successful use of temozolomide to treat pituitary carcinomas appeared in 2006 (5,6). To date, 16 cases have been treated (5,6,13,16,17,21-23,25). The time between disease presentation to temozolomide administration was 5–23 years (mean: 10.7 years). The group included nine PRL-producing tumors, five ACTH-producing tumors, three clinically non-functional tumors, and three silent corticotroph carcinomas. Eleven of the 16 patients (69%) experienced a clinical and radiological response to temozolomide. Assessment of MGMT immunoreexpression was only
available in 11 patients; only one patient with high-level immunoexpression responded to treatment.

**Morphological changes**

Morphological comparisons of pathology before and after temozolomide treatment were performed in three cases: all were patients with adenomas. One was a non-responder who exhibited no changes (10) and two were responders (8,23) whose tumors after treatment demonstrated hemorrhage, necrosis, focal fibrosis, inflammatory infiltrates, fewer mitoses, and a low Ki-67 labeling index, as well as neuronal transformation. The latter is considered to be a metaplastic phenomenon and has been observed in a variety of untreated endocrine neoplasms, including GH cell adenomas (50).

**DISCUSSION**

Response to treatment

In patients who respond to temozolomide, three basic patterns of radiographic changes are seen on MRI: tumor necrosis and hemorrhage (7,8), cystic change (19), and shrinkage (9,11-14). Such changes may be seen as early as two months after the onset of treatment.

In the tumors that respond to temozolomide, the clinical response is rapid and associated with prompt decreases in chiasmatic compression and mass effects. In patients with endocrine-active PRL- and ACTH-producing tumors, an almost immediate reduction in plasma hormone levels becomes apparent after commencement of therapy. Thus, it is possible to quickly evaluate the treatment response.

**MGMT immunoexpression and MGMT promoter methylation**

The inverse relationship between MGMT immunoexpression and temozolomide response was first reported in two patients with aggressive pituitary adenomas (10). The observation was subsequently confirmed by McCormack et al. who assessed MGMT immunoreactivity in a PRL cell carcinoma and an aggressive GH-producing adenoma (13).

In both studies, tumors with low-level MGMT immunoexpression demonstrated clinical and radiological responses to temozolomide therapy. Other authors have reported similar findings (51). Thus, the demonstration of MGMT immunoreactivity appears to be useful for predicting the response of aggressive pituitary adenomas and carcinomas to temozolomide treatment.

The reports of Kovacs et al. (10) and McCormack et al. (13,51) underscore the inverse relationship between MGMT immunoexpression and the efficacy of temozolomide therapy, and this relationship has also been noted in high-grade gliomas (46-48,52). Whereas the standard method for evaluating MGMT status in gliomas is the identification of promoter methylation (47), immunohistochemical detection of MGMT expression is an attractive alternative. It represents an inexpensive, readily accessible technology that is available to most laboratories (53,54). Whereas most reports pertaining to gliomas and temozolomide therapy are based on promoter methylation status, data relating to pituitary neoplasms are based on MGMT immunoeexpression (24,51).

Although several recent reports of aggressive pituitary tumors that were successfully treated with temozolomide have reported absent or low immunohistochemical expression of MGMT as a factor, one patient whose tumors exhibited higher levels of MGMT staining also experienced clinical improvement and tumor shrinkage following treatment (23). It is of note that some tumors with no promoter methylation also respond to therapy (22,23). These observations challenge the notion that MGMT promoter methylation is a reliable predictor of treatment response. Indeed, two recent studies on MGMT promoter methylation and the temozolomide response in eight aggressive adenomas and seven pituitary carcinomas found no association between promoter methylation status and response (22,23). Salehi et al. (55) did not find a close correlation between MGMT immunoexpression and MGMT promoter methylation in a study on aggressive pituitary adenomas and carcinomas. Thus, the utility of MGMT promoter methylation for the selection of patients who might respond well to temozolomide treatment remains controversial and an active focus of further research. The problem is that many tumors possess an admixture of MGMT immunopositive and immunonegative cells. Obviously, in such instances, it is difficult to predict overall the responsive to temozolomide.

To date, MGMT immunoexpression has been documented in 23 adenomas and 11 carcinomas. In 18 tumors, MGMT labeling was low and correlated with a good therapeutic response to temozolomide (14/18 cases). In eight instances, MGMT staining was intermediate: five tumors responded well and three did not. In eight patients with high MGMT immunoexpression, only one responded positively. Thus, tumors featuring low- and intermediate-level MGMT immunoexpression (n = 26), when compared with those with high MGMT immunoexpression (n = 8), showed a good response to temozolomide in 19/26 (73%) versus 1/8 (13%) cases (p = 0.0039; two-tailed Fisher’s exact test).

**Suggested indications for using temozolomide treatment**

Based on the published cases and the reported response rates, temozolomide therapy can be recommended when other options fail, particularly in the following instances: (1) aggressive PRL-producing tumors that are resistant to bromocriptine or cabergoline and continue to grow after surgery and radiotherapy; (2) aggressive ACTH-producing tumors, especially Crooke cell and Nelson syndrome variants that cannot be cured by surgery and radiotherapy; (3) recurrent, clinically non-functional tumors exhibiting continued growth after repeated surgeries and radiotherapy; (4) pituitary carcinomas.

Temozolomide has been documented as valuable for the treatment of aggressive pituitary adenomas and carcinomas. The clinical and radiological responses are encouraging: 60% of aggressive adenomas and 69% of pituitary carcinomas respond well to treatment. An inverse correlation exists between MGMT immunoexpression and the therapeutic response to temozolomide. Based upon our literature review, a significant proportion of the adenohypophysial tumors that are responsive to temozolomide show low-level MGMT immunoexpression, whereas only one tumor showing high-level immunoexpression was found to respond. The use of immunohistochemistry for determining MGMT immunoexpression appears to be a promising guide for therapeutic decision-making (13,53). Obviously, all available methods for assessing the likelihood of a positive temozolomide response should be utilized. We feel strongly that the determination of MGMT immunoreactivity is of clinical value and that MGMT promoter methylation status should
be determined as well. The molecular mechanisms that affect MGMT expression remain to be fully elucidated. Targeted modulation of MGMT may be used in patients who are otherwise not responsive to temozolomide therapy. Future therapies that incorporate different dosing regimens or other drugs may improve the tumor responsiveness.

DISCLOSURE
The authors have no personal financial or institutional interest in any pharmaceutical agents or testing devices described herein.

ACKNOWLEDGMENTS
The authors are grateful to the Jariuskowsky and Lloyd Carr Harris Foundation for their continued support. The authors thank Mrs. Denise Case from the Mayo Clinic for her excellent assistance and secretarial support.

AUTHOR CONTRIBUTIONS
Ortiz LD, Syro LV, Scheithauer BW, and Kovacs K conceived the study and wrote the manuscript. Ortiz LD, Syro LV, and Rotondo F searched the literature and extracted the data. Rotondo F, Uribe H, Fadul CE, and Horvath E contributed to the initial draft of the manuscript. All authors contributed to the critical revision of the manuscript and approved the final version.

REFERENCES
1. Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009;12(3):256-60, http://dx.doi.org/10.1007/s11125-008-0153-x.
2. Kaltas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(9):3089-99, http://dx.doi.org/10.1210/jc.2004-2231.
3. Colao A, Ochao AS, Aurienma RS, Faggiano A, Pivonello R, Lombardi G. Pituitary carcinomas. Front Horm Res. 2010;38:94-108, http://dx.doi.org/10.1007/00318949.
4. Perricone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WFJr., et al. Temozolomide and pituitary tumors. Acta Neuropathol. 2009;118(3):454-62, http://dx.doi.org/10.1007/s00401-009-0911-z.
5. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JAJr., Vance ML, et al. Temozolomide for the treatment of brain tumors in patients with gliomas: a phase II pilot study. Clin Cancer Res. 2004;10(11):3885-91, http://dx.doi.org/10.1158/1078-0432.CCR-04-0135.
6. Ravey G, Sturm N, de Frainoit F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4929-9, http://dx.doi.org/10.1210/jc.2010-06442.
7. Debono M. Management of MGMT negative tumors: correlation of clinical outcome with MGMT promoter methylation status. Cancer. 2006;105(3):667-76, http://dx.doi.org/10.1002/cncr.21605.
8. Morin E, Berthelet P, Weisnegal J, Bidlingmaier M, Meri S. Role of MGMT methylation status in the primary treatment strategy of glioblastoma. J Neurooncol. 2006;79(4):804-12, http://dx.doi.org/10.1007/s11060-006-0014-1.
9. Byrne S, Karapetis C, Vrodos N. A novel use of temozolomide in a patient with recurrent anaplastic astrocytoma. J Neurooncol. 2009;94(2):173-5, http://dx.doi.org/10.1007/s11060-009-0014-1.
10. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (Temodar) and capacetabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor. Pituitary. 2011;14(4):418-24, http://dx.doi.org/10.1111/j.1365-2541.2010.01536.x.
11. Debono M, Bridgewater C, Ross R, Newell-Price J. Treating an aggressive pituitary tumour to temozolomide therapy. Acta Neuropathol. 2006;115(2):261-2, http://dx.doi.org/10.1007/s00401-007-0279-5.
12. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, et al. Treatment of Nelson’s syndrome with temozolomide. Eur J Endocrinol. 2009;160(1):115-9.
13. Hermann K, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71(2):226-33, http://dx.doi.org/10.1111/j.1365-2265.2008.03487.x.
35. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401-6, http://dx.doi.org/10.1200/JCO.2005.03.6046.

36. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5(2):144-51, http://dx.doi.org/10.1634/theoncologist.5-2-144.

37. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12(9):1114-23, http://dx.doi.org/10.1634/theoncologist.12-9-1114.

38. Shacham-Shmueli E, Beny A, Geva R, Blachar A, Figer A, Aderka D. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J Clin Oncol. 2011;29(10):e262-5, http://dx.doi.org/10.1200/JCO.2010.32.0242.

39. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27(23):3861-7, http://dx.doi.org/10.1200/JCO.2008.20.7944.

40. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma: look to the future. Nat Clin Pract Oncol. 2008;5(8):476-86, http://dx.doi.org/10.1038/ncponc1155.

41. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12(2):328-31, http://dx.doi.org/10.1158/1078-0432.CCR-05-2543.

42. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008;16(1):59-65.

43. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20(9):2388-99, http://dx.doi.org/10.1200/JCO.2002.06.110.

44. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O^6^-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):797-7.

45. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 2009;29(10):3759-68.

46. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-4, http://dx.doi.org/10.1056/NEJM200010053431901.

47. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):1007-1003, http://dx.doi.org/10.1056/NEJMoa043331.

48. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O^6^-methylguanine-DNA alkyltransferase analysis and response to Temozol in newly diagnosed malignant glioma. J Clin Oncol. 1998;16(12):3851-7.

49. Kaltasas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83(12):4233-8, http://dx.doi.org/10.1210/jc.83.12.4233.

50. Scheithauer BW, Horvath E, Kovacs K, Lloyd RV, Stefanau L, Buchfelder M, et al. Prolactin-producing pituitary adenoma and carcinoma with neuronal components: a metaplastic lesion. Pituitary. 1999;1(3-4):197-205, http://dx.doi.org/10.1023/A:1009913303109.

51. McCormack AJ, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011;41(10):1133-48, http://dx.doi.org/10.1111/j.1365-2362.2011.02520.x.

52. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, et al. O^6^-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24(21):3431-7, http://dx.doi.org/10.1200/JCO.2006.05.7265.

53. Widhalm G, Wolfsberger S, Preusser M, Woerther A, Kotter MR, Czech T, et al. O^6^-Methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer. 2009;115(5):1070-80, http://dx.doi.org/10.1002/cncr.24053.

54. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R. MGMT immunohistochemical expression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? J Clin Oncol. 2002;20(9):2388-99, http://dx.doi.org/10.1200/JCO.2002.06.110.

55. Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, et al. MGMT promoter methylation and immunohistochemical expression in aggressive pituitary adenomas and carcinomas. J Neurooncol. 2011;104(3):647-57, http://dx.doi.org/10.1007/s11060-011-0532-6.